Design and Evaluation of Doxofylline Immediate Release Tablets

Bharathi Agirela*, Nandini.Akula, Nikitha.Ponnam, Chandra Sekhar Naik.D
Department of pharmaceutics, KVSR Siddhartha College of Pharmaceutical Sciences, Vijayawada-520010, India

ABSTRACT

Doxofylline a bronchodilator and anti-tussive is used for chronic obstructive pulmonary disease (COPD) and asthma that acts as phosphor diesterase inhibitor with minimum cardiovascular side effects due to low affinity for adenosine receptors (both A1 and A2) unlike theophylline and other xanthine derivatives. Doxofylline is water soluble and comes under biopharmaceutical classification class III with high solubility and low permeability. In this study an attempt has been made in development and to evaluate the formulation of Doxofylline tablets of 400mg and these compressed tablets were tested for friability, thickness, disintegration time, hardness, weight variation and assay. The formulation trial F4 was optimized considering the drug release profile and the disintegration time of tablets as they were very close to the reference product values. From this study, it may be concluded that for Doxofylline tablets, F4 stands as a successful formulation and can be manufactured with reproducible characteristics from batch to batch to match the release profile with the reference product. The in-vitro release of Doxofylline tablets was studied in 900 ml of distilled water as dissolution medium using an I.P dissolution paddle assembly at 100rpm and 37±2°C for 45min.

Keywords: Doxofylline tablets, Micro crystalline cellulose, HPLC, Antiasthmatic
INTRODUCTION

Administration of medications can be possible through numerous routes. Regardless, oral route of administration is most helpful route to administration of drugs for fundamental impact contrasted with different routes of administration. Oral medications are considered as the first investigated in the discovery and development of pharmaceutical active ingredients and pharmaceutical formulations, due to ease of administration, cost effective manufacturing, and patient acceptance.

Bronchial asthma is a critical issue, particularly in developing nations. Over the most recent couple of decades, asthma has demonstrated an expanding commonness influencing kids and youngsters. It involves both inflammation and bronchoconstriction and hence the treatment of asthma aimed at reducing inflammation and bronchoconstriction. In India asthma is assessed to associate with 338% in youngsters and 212% among grownups, common stinkers. For the treatment of Asthma and COPD, Xanthine derivatives are utilized since an extensive period of time. Doxofylline is a xanthine subsidiary. It works by strain of phosphodiesterase and furthermore utilized for upkeep treatment in patients enduring with asthma and unending obstructive pneumonic ailment (COPD). Doxofylline is widely metabolized in liver by demethylation and oxidation to a degree of 80-90% and half plasma protein bound Elimination half-life(t½) is around 67 hour and day by day measurements is 200-400mg a few times in multiday. Doxofylline goes underclass III of BCS arrangement and water dissolvable.

METHODS AND MATERIALS

Materials
Doxofylline (Biocon Ltd.,), Microcrystalline Cellulose (Viajy Enterprises), Lactose( Ramesh Trading Co.,), Sodium Starch Glycolate ( Amishi Drugs & Chemicals Ltd.,), Colloidal Silicon dioxide (Cabot Sanmar Ltd.,), Isopropyl Alcohol (Nikitha Chemicals), Polyvinyl Pyrrolidone K-30 (Kollidone) (Ramesh Trading Co.,), Talc (GangotrilorganicsPvt Ltd.,), Magnesium Stearate (Global Medicines Ltd.,)

Methods
Construction of calibration curve
Doxofylline can be quantitatively analyzed by various techniques. In the present study, doxofylline was estimated by U.V. spectrometric method.

Procedure:
An accurately weighed quantity of Doxofylline (100mg) was dissolved in 100ml of distilled water to generate stock solution having concentration of 1mg/ml. 1ml of stock solution was further diluted to 100ml to produce standard solution was further diluted to 100ml to produce standard solution having a concentration of 10mcg/ml. from this, 1, 2, 4, 6 and 8ml were taken and diluted to 10ml. it gives various concentrations of 1, 2, 4, 6 and 8mcg/ml respectively. The absorbances of the solutions were measured at 273nm against blank (distilled water) using U.V-Visible spectrometer.

PERFORMANCE STUDIES

Performance testing is the first step in the rational development of the dosage forms. It can be defined as an investigation of physical and chemical properties of drug substance alone and combined properties of a drug substance alone and combined with excipients.

The objective of performance testing is to generate information useful to the formulator in developing stable and bioavailable dosage forms that can be mass produced.

The use of performance parameters minimizes the chances in formulating an acceptable, safe, efficacious and stable product and at the same time provides the basis for optimization of the drug product quality.

The preformulation scientists must consider the following:

- Available pharmacokinetic data
- Anticipated dose
- Nature of the information of the formulator should have or would like to have.

**Determination of the densities:**

**Apparent bulk density (bulk):**

Bulk density is the ratio of the given mass of powder to its bulk volume. The bulk density, as a measure used to describe packing materials or granules, was determined transferring the accurately weighed amount of powder sample to the granulated cylinder with the aid of the funnel. The powder was leveled carefully without compacting and the unsettled apparent volume \( (V_0) \) was noted. The bulk density in g/ml was calculated by formula

\[
\text{Bulk density} = \frac{M}{V_0}
\]

Where \( M \) = weight of the sample taken

**Tapped density:**

After noting down the volume \( (V_0) \) in the bulk density testing, the graduated cylinder was tapped mechanically using a suitable tapped density tester density tester that provides a fixed tap of 14 ±
2nm at 300 drops per minute, for 500 times initially and tapped volume ($V_a$) was measured to the nearest graduated unit. The tapping was repeated for an additional 750 times and tapped volume was measured to the nearest graduated unit. The tapping was repeated of an additional 750 times and tapped volume ($V_b$) was measured to the nearest gratitude unit. If the difference between the two measurements is <2%, $V_b$ is the final tapped volume ($V_f$). If the difference is >2%, the tapping was repeated at the increments of 1250 taps until the difference between the two successive measurements is <2%. The tapped density, in g/ml was calculated by the formula

$$\text{Tapped density} = \frac{M}{V_f}$$

Where $M =$ weight of the sample taken for bulk density testing

**Carr’s Index (% compressibility):**

The compressibility and hausner’s ratio are the measures of the propensity of a powder to be compressed. As such, these are the measures of relative importance of inter particulate interaction. In a free flowing powder, such interactions are less significant and the bulk and tapped densities will be closer in value. For poor flowing materials, the bulk and tapped densities will be observed. These differences are reflected in the compressibility index and the Hausner’s ratio. Based on the apparent bulk density and the tapped density, the percentage compressibility of the bulk drug was determined by using the following formula

$$\% \text{Compressibility} = \frac{Tapped\ density - Bulk\ density}{Tapped\ density} \times 100$$

**Hausner’s Ratio:**

The ratio of tapped density to the bulk density of the powders is called the Hausner’s Ratio

$$\text{Hausner’s Ratio} = \frac{Tapped\ density}{Bulk\ density}$$

The following table shows the acceptance criteria for flow properties of the compound according to USP.

| Compressibility index (%) | Flow properties  | Hausner’s ratio |
|--------------------------|------------------|-----------------|
| <10                      | Excellent        | 1.00-1.11       |
| 11-15                    | Good             | 1.12-1.18       |
| 16-20                    | Fair             | 1.19-1.25       |
| 21-25                    | Passable         | 1.26-1.34       |
| 26-31                    | Poor             | 1.35-1.45       |
| 32-37                    | Very poor        | 1.46 -1.59      |
| >38                      | Very very poor   | >1.60           |
Formulation of tablets:

Table 1. Formulation trials:

| S.no | Ingredients                      | Formulation (mg) |
|------|----------------------------------|------------------|
|      |                                  | F1   | F2   | F3   | F4   | F5   |
| 1.   | Doxofylline                      | 400  | 400  | 400  | 400  | 400  |
| 2.   | Micro crystalline cellulose      | 87   | 85   | 75   | 80   | 85   |
| 3.   | Lactose                          | 39   | 34   | 34   | 34   | 35   |
| 4.   | Sodium starch glycolate          | 20   | 20   | 25   | 20   | 20   |
| 5.   | Colloidal silicon dioxide        | 9    | 8    | 8    | 8    | 9    |
| 6.   | Isopropyl alcohol               | QS   | QS   | QS   | QS   | QS   |
| 7.   | PVP K-30                        | 12   | 25   | 25   | 25   | 18   |
| 8.   | Sodium starch glycolate          | 23   | 18   | 23   | 23   | 23   |
| 9.   | Colloidal silicon dioxide        | 7.2  | 7.2  | 7.2  | 7.2  | 7.2  |
| 10.  | Talc                             | 20   | 20   | 20   | 20   | 20   |
| 11.  | Magnesium stearate              | 3    | 3    | 3    | 3    | 3    |

Post Compression Parameters

Evaluation of tablets

The tablets were subjected to the following quality control tests

Physical appearance

As one of the quality control procedures, tablets should be inspected for smoothness, absence of chips and other undesirable characteristics. If they are colored, this would include examination of mottling and other evidence of non-uniform color distribution except where they are used intentionally.

Weight variation

Approximately 20 tablets were randomly selected from each formulation and their average weight was calculated using digital balance. Individual weight of each tablet was also calculated using the same and compared with average weight

Hardness

The hardness test is performed to measure the tablet strength. Tablet should be hard enough to withstand packing and shipping. Schlenzner hardness tester was used for the determination of hardness of tablets. Place the tablets between the jaws for each measurement; orient the tablet in the same way with respect to the direction of the application of the force. Carry out the measurement on 10 tablets, taking care that all fragments of the tablets have been removed before each determination

Thickness and diameter
The dimensional specifications like diameter and thickness can be accomplished by the use of vernier calipers. The thickness of the tablet is mostly related to the tablet hardness and can be used as an initial control parameter.

**Friability**

The friability test gives an indication of the ability of the tablets to resist chipping and abrasion on handling during packaging and shipping. Usually for conventional tablets, friability value of 1.0% or less desirable. The weight of 20 tablets was determined and then they were placed in the Roche friabilator, which makes 100 revolutions at 25rpm. The tablets were then removed, dedusted and reweighed. The friability is expressed as the loss of weight and it is calculated as a percentage of the initial weight.

$$\%\text{Friability} = \left(1 - \frac{W}{W_0}\right) \times 100$$

Where, $W$ = initial weight of 20 tablets, $W_0$ = weight of 20 tablets after 100 revolutions

For compressed tablets, the loss less than 1% in weight are generally considered acceptable.

**Disintegration test**

The disintegration time is considered to be one of the important criteria in selecting the best formulation. It is a measure of the time required for a group of tablets disintegrates into particles which will pass through a 10 mesh screen. Generally, the test is useful as a quality assurance tool for conventional dosage forms.

One tablet each was placed into 6 tubes of the basket rack assembly of disintegration tester water maintained at $37\pm 2^\circ\text{C}$ and the apparatus was operated for 30 sec. If one or two tablets fail to disintegrate, the test is repeated using 12 tablets. The requirement is meant if not less than 16 of the total of 18 tablets tested disintegrate. For conventional tablets, the B.P. requires that the tablets disintegrate in 15min.

**Dissolution test**

The dissolution test measures the rate of release of the drug from the dosage form in-vitro; it is usually expressed as extent of dissolution occurring after a given time under specified conditions. For effective absorption of oral solid dosage form, simple disintegration of the dosage form is not adequate and the dissolution of the drug into surrounding medium plays the vital role. Though dissolution is not a predictor of the therapeutic efficacy it can be looked upon a tool. This can provide valuable information about biological availability of the drug and batch consistency. Dissolution is considered as one of the drug and batch to batch consistency. Dissolution is considered as one of the important quality control tests performed for pharmaceutical dosage form.

**Standard preparation**

[www.ajphr.com](http://www.ajphr.com)
An accurately weighed quantity of about 0.100 gms of doxofylline working standard was transferred into a 100ml volumetric flask and 70ml of dissolution medium was added and sonicated to dissolve the content. The volume was made up to the mark with dissolution medium and mixed well. 1ml of this solution was diluted to 50ml with dissolution medium.

Method:
The absorbance of the standard preparation and sample were measured in a UV Visible spectrophotometer at 273nm using dissolution medium as a blank. The release of Doxofylline in the % with respect to label claim was calculated using the following expression-

**Calculation: % per tablet**

\[
\frac{AT}{AS} \times \frac{WS}{100} \times \frac{1}{50} \times \frac{900}{1} \times \frac{100}{5} \times \frac{P}{100} \times \frac{100}{400} = \text{_______\%}
\]

Where AS = absorbance of standard solution, AT = absorbance of sample solution
WS = weight of Doxofylline working standard (WS) taken for standard preparation in gms, P = %potency of Doxofylline WS on such basis

**Assay/drug content (By HPLC)**

**Reagents:**
HPLC grade acetonitrile, Milli Q water, Doxofylline working standard, Chromatographic conditions, **Mobile phase:** a filtered and degassed mixture of water, acetonitrile in the ratio of 85:15, **Column:** C8, 4.6mm×250, 5µ, **Wavelength:** 273nm, **Flow rate:** 1.3ml/min, **Load:** 10µL, **Run time:** 25min

Standard preparation 50mg of doxofylline WS was taken in 100ml of volumetric flask and made up to the volume with distilled water

**Sample preparation**
About 620mg of tablet powder (equivalent to 400mg) was weighed, placed in a 200ml volumetric flask, shaken well and made up to the volume with water. After 30min, the contents of the flask were centrifuged at 500rpm for 15min. then, 5ml of the supernatant was taken and diluted to 20ml with distilled water.

**Procedure**
Both the standard and the sample preparations were separately injected into the liquid chromatograph and the peak areas were recorded.

**Calculation:**

\[
\frac{At}{As} \times \frac{Sw}{100} \times \frac{200}{Tw} \times \frac{20}{5} \times \frac{P}{100} \times \text{Avg wt}
\]
Where,

$A_t$ = peak area due to doxofylline in sample preparation.

$A_s$ = peak area due to doxofylline in sample preparation.

$S_w$ = weight of doxofylline WS taken in mg.

$A_{vgw}$ = average weight of tablet in mg

$P$ = purity of doxofylline WS used.

**Stability studies**

The finalized formulations will be packed in suitable packaging like blisters and strips and the they will be kept at different temperatures, humidity conditions to check the stabilities as per ICH guidelines and the samples will be analyzed for their physical and chemical properties.

The selected trial (F4) tablets were packed in PVC/ Aluminum blisters pack and placed in stability chambers of 25°C/ 60%RH, 40°C /75% RH. The samples were withdrawn and analyzed as per stability protocol.

**RESULTS AND DISCUSSION**

**Table 2. Calibration curve data of Doxofylline**

| S.no | concentration (mcg/ml) | Absorbance At 273nm |
|------|------------------------|---------------------|
| 1.   | 0                      | 0.00                |
| 2.   | 1                      | 0.0374              |
| 3.   | 2                      | 0.0743              |
| 4.   | 4                      | 0.1484              |
| 5.   | 6                      | 0.2232              |
| 6.   | 8                      | 0.296               |

**Figure 1: Calibration curve data of Doxofylline**

**Drug excipient compatibility study**

[www.ajphr.com](http://www.ajphr.com)
Pre-compression studies

The values of pre-compression parameters evaluated were found to be within the prescribed limits and indicated good free flowing property of the formulations.

| Formulation | Bulk Density (mg/ml) | Tapped Density (mg/ml) | Carr's Index (%) | Hausner's Ratio | Lod | Assay |
|-------------|----------------------|------------------------|------------------|-----------------|-----|-------|
| F1          | -                    | -                      | -                | -               | -   | -     |
| F2          | 0.587                | 0.786                  | 25.31            | 1.339           | 1.9 | 99.46 |
| F3          | 0.562                | 0.743                  | 24.36            | 1.322           | 1.8 | 99.62 |
| F4          | 0.5264               | 0.689                  | 23.68            | 1.309           | 1.8 | 101.62|
| F5          | 0.59                 | 0.733                  | 19.51            | 1.242           | 1.8 | 99.22 |

Post compression studies

The data obtained for post compression parameters such as appearance, average weight, weight variation, thickness, hardness, diameter, friability, disintegration and assay.

In all the formulations, friability value was less than 1% indicating that the tablets formulated are mechanically stable. All the tablets passed the weight variation test as the percent weight variation was within specified limit.

The present investigation was undertaken to formulate Doxofylline tablets by wet granulation method for the treatment of bronchial asthma and chronic obstructive pulmonary disorder and compare their drug release patterns with the reference product. All the experimental formulation
batches have been subjected to various evaluations viz., average weight, height, thickness, friability, disintegration, dissolution and assay.

Table.4.Post compression parameters of F2-F5

| S.No | Parameters       | F2                          | F3                          | F4                          | F5                          |
|------|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| 1.   | Appearance      | White, flat & round shaped tablets having one side scored | White, flat & round shaped tablets having one side scored | White, flat & round shaped tablets having one side scored | White, flat & round shaped tablets having one side scored |
| 2.   | Thickness (mm)  | 3.79                        | 3.82                        | 3.802                       | 3.806                       |
| 3.   | Diameter (mm)   | 12.93                       | 12.94                       | 12.946                      | 12.95                       |
| 4.   | Hardness (kg/cm²) | 5.5                      | 5.0                         | 4.5                         | 4.5                         |
| 5.   | Friability (%)  | 0.18                        | 0.39                        | 0.76                        | 0.93                        |
| 6.   | Average weight (mg) | 622.2                  | 620.7                       | 619.66                      | 621.0                       |
| 7.   | Weight variation | Complies                   | Complies                   | Complies                   | Complies                   |
| 8.   | Disintegration time | 9 min 25 sec               | 8 min 40 sec               | 3 min 29 sec               | 4 min 47 sec               |
| 9.   | Assay (%w/w)    | 99.12                      | 98.87                      | 100.04                     | 99.52                       |

Formulation F1 was made by using povidone K-30 (1.94%). But the binder was not sufficient enough to affect granulation. So, the granules were not formed. Hence, this formation was a failure.

Formulation F2 was made by using povidone K-30 (4.03%) and sodium starch glycolate (2.9%) in extra granulation. The hardness and disintegration time were found to be 5.5kg/cm2 and 9min 25sec respectively. The drug release being 70.98% in 45min was not satisfactory.

Formulation F3 was made by using povidone K-30 (4.03%) and sodium starch glycolate (4.03%) intra granulation. The hardness and disintegration time were found to be 5.0kg/cm2 and 8 min 40 sec respectively. The drug release was not satisfactory (75.12%).

Formulation F4 was made by using povidone K-30 (4.03%), avicel (12.9%) and sodium starch glycolate (3.23% in intra granulation and 3.71% in extra granulation). The hardness and disintegration time were found to be 4.5kg/cm2 and 3min 29 sec respectively. The drug release was 100.42% within 20min. These results were very much close to those of reference product.

Formulation F5 was made by using povidone K-30 (2.9%), avicel (13.7%) and sodium starch glycolate in the same concentrations as in F4. The hardness and disintegration time were found to be 4.5kg/cm2 and 4min 47 sec respectively. The drug release was 100.21% in 45min but only 89.12% in 20min as compared to the reference product.

As the formulation trial, F4 was similar to the reference product than the formulation trial F5; it was finalized as the optimized formulation

Table.4.Dissolution profiles of the trial formulations

| S.no | Time (min) | Cumulative percentage of drug release |
|------|------------|--------------------------------------|
|      | Reference  | F2 | F3 | F4 | F5                      |

www.ajphr.com
SUMMARY AND CONCLUSION

In this study, an attempt has been made to develop a formulation for doxofylline tablets of 400mg. The linearity of doxofylline standard curve was checked in the dissolution medium i.e., distilled water. It was found to be linear in the range of 1 MCG/ml to 8MCG/ml. The dissolution profile of the reference product was evaluated in the dissolution medium. It was noticed that the product release more than 85% of the drug within 20min. Performulation studies were done initially and the results directed the further course of formulation. With the data from literature review, formulation trials (F1 to F5) were started using wet granulation method. Granules were evaluated for tests such as bulk density, tapped density, compressibility index and hausner’s ratio before being punched into tablets. The compressed tablets were tested for weight variation, thickness, hardness, friability, disintegration time and assay. The dissolution profile of all the four trials were evaluated and compared with the reference product. Amongst all the four formulations, the release profile of the trial formulation F4 was found to be similar with the respect to the reference listed drug product and hence it was selected for the further study.

The stability study for the selected formulation (F4) was performed per ICH guidelines. The selected trial tablets (F4) were packed in PVC/aluminum blister lack and placed in the stability conditions.
chambers of 25°C/60%RH and 40°C/75%RH for 3 months and analyzed at regular intervals. It was found that the product is stable in both the conditions as it showed a negligible change in drug content after storage in various condition for 3 months. The formulation trial F4 was optimized considering the drug release profile and the disintegration time of the tablets as they were very close to the reference product values. From this study, it may be concluded that for Doxofylline tablets, F4 is a successful formulation and it can be manufactured with reproducible characteristics from batch to match the release profile with the reference product. The findings of the present study ensure the company to launch the product in the market in near future.

ACKNOWLEDGMENT

Authors are very much thankful to Siddhartha academy of general and technical education and principal of KVSR Siddhartha college of pharmaceutical sciences for providing facilities.

REFERENCES

1. Akbar, Mohd& Panda, Niranjan & Venketeswar Reddy, A. (2015). Formulation and Evaluation of Doxofylline Sublingual Tablets Using Sodium Starch Glycolate and Crosscarmellose Sodium as Superdisintegrant. International Journal of Pharmaceutical Research & Allied Sciences. 4. 90-100.

2. Aulton. M; Pharmaceutics: The Science of Dosage Form Design; International Student edition. Pg: 304-321, 347-668, 616.

3. B Zhou, SX Cai, F Zou, CQ Cai, HJ Zhao, “Effect of doxofylline on calcium activated potassium channels in human peripheral blood eosinophils in asthma”. [http://www.ionchannels.org/redirect.PHP?linkurl=http://www.ncbi.nlm.nih.gov/enterz/query.fcgi?pmid=16409781&doctype=abstract]

4. Banker. G and Rhodes. C; Drug and Pharmaceutical Sciences: Modern Pharmaceutics; Third version, Volume- 72, Pg no: 333-394.

5. Bologna.E, Lagana. A, Terracino. D, Bolignari. P and Biffignandi. P, “Oral and intravenous pharmcokinetic profiles of doxofylline in patients with chronic bronchitis”. [J-Int-Med-Res. 1990 Jul-Aug; 18(4): 282-8]

6. Checchini M, Magni M, Franzini C, Vaccarella A and Omboni E. “Controlled clinical study of doxofyllinevs aminophylline in the treatment of acute cardio respiratory insuffiency syndrome”. [http://www.ncbi.nlm.nih.gov/sites]
7. Chowhan. Z; Pharmaceutical Technology: Excipients and their Functionality in Drug Product Development; 1993; (9) CIMS®- 103; Oct ’08 – Jan ’09, Indian Update – 4, Pg no:19, 396.

8. Dali Shukla, SubhashisChakraborty, Sanjay Singh &Brahmeshwar Mishra, Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease Expert Opin. Pharmacother, 2009, 10(14):2343-2356.

9. Dilip M. Parikh, Handbook of Pharmaceutical Granulation Technology, Pg no: 3.

10. Dini FL, Pasini G, Cortellini G, Cani E, Bettini R, Garagnani A, Gobbi G, Greco A, Onorato G, Pasini P, et al. “Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: double-blind placebo-controlled clinical trial of doxofylline versus theophylline and bamifylline”. [Int J. ClinPharacol Res. 1993;13(6):305-16]

11. Dolcetti. A, Osella. D, De Filippis.G, Carnuccio. C, Grossi. E, “Comparison of intravenously administered doxofylline and placebo fo the treatment of severe acute airways obstruction”. [J-Int-Med-Res. 1998 Jul-Aug; 16(4): 264-9]FD Martinez. Genes, environments, development and asthma. EurRespir J. 2007;29(1):79–184.[PubMed]

12. Franzone Jose S. and De Vercelli, Sergio, US Patent No: 4868186 for the invention of “New derivatives of Theophylline-Theophyllinemethyldithiolan and theophylline methyl dithianyl derivatives having antibronchospastic, antitussive and mucolytic activities”. [http://www.freepatentsonline.com/4868186.html]

13. Franzone Jose S. and Tamietto. T, US Patent No: 4187308 for the invention of the compound 7- [2′-(1’, 3’-dioxolanylmethyl]-theophylline having antibronchospastic and antitussive activity. [http://www.freepatentsonline.com/4187308.html]

14. Franzone Jose S., Italian Patent Application No: 21370-A/80, describing a class of variously substituted theophyllinemethyldioxolan derivatives characterized by antitussive and antibronchospastic activity. [http://www.freepatentsonline.com]

15. He Zhonggui and GuoXiaolei, patent for Doxofylline osmotic pump controlled releasing preparation and its production”. [http://www.chemyq.com/patrntfem/pt68/671462_E838B.htm]

16. Herbet A. Lieberman, Leon Lachmann and Joseph  B. Schwartz; Pharmaceutical dosage forms, Tablets: Volume II, second edition, marcel Dekker Inc., New York (1990), Pg no:109, 201-204.
17. Hui-Feng Huang, Yan Lu, Hai-Bing He and Xing Tang “Preparation and Bioavailability of Sustained-Release Doxofylline Pellets in Beagle Dogs” – Drug Development and Industrial Pharmacy, Volume 34, Issue 7 July 2008, Pg no:676 – 682.

18. Indian Pharmacopoeia -2007.

19. J.H. Lee, H.W. Namgung, S. Y. Kwon, H. I. Yoon and C. T. Lee, “The pharmacokinetic profiles of oral doxofylline and factors influencing the serum level”. [European Respiratory Society-Annual Congress 2007,P2116]

20. James Swarbrick, James C. Boylan; Encyclopedia of Pharmaceutical Technology, Second edition, Volume 1, Pg no:121-160

21. James Swarbrick, James C. Boylan; Encyclopedia of Pharmaceutical Technology, Second edition, Volume 1, Pg no: 348-355, 385-400, 401-418.

22. James Swarbrick, James C. Boylan; Encyclopedia of Pharmaceutical Technology, Second edition, Volume 1, Second edition, Volume 1, Pg no:285.

23. Leon lachmann, Herbert A. Lieberman, joseph L. Kanig; The Theory and Practice pf Industrial Pharmacy, Third edition, Pg no:317-321, 293-345, 346-373.

24. M Chan-Yeung, J Manfreda, H Dimich-Ward. A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants. Arch PediatrAdolesc Med. 2000;154(7):657–63. [PubMed]

25. M. Lazzaroni, E. Grossi, G. Bianchi Porro, “The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients”. [http://www3.inter.Wiley.com/journal/119377806/abstract]

26. Martindale – The Extra Pharmacopoeia, Third Edition, Pg no:1317.

27. Melillo.G, Balzano.G, Jodice.F, De Felicw.A, Campisi. V, Capone.M, Di Fillipo.A, Foddai.G, Franzone.JS, Grossi.E, et al. “Treamt of reversible chronic airways obstruction with doxofylline compared with slow-realease theophylline: a double-blind, randomized, multicenter trial”. [Int J Clin Pharmacol Res.1989; 9(6):397-405]

28. Moest, Thomas and Pich, Claus H., US Patent No: 5160469 for “Manufacture of pellets of Xanthine derivatives”. [http://www.freepatentsonline.com/5160469.html]

29. N.K. Jain, Pharmaceutical Product Development.

30. S Choudhry, MA Seibold, LN Borrell. Dissecting complex diseases in complex populations. Proc Am Thorac Soc. 2007;4(3):226–33. [PMC free article] [PubMed]

31. S Factsheet on Asthma in India. South Asia Network for chronic Disease, New Delhi, India, 2010. Available
from: http://www.sancd.org/uploads/pdf/Asthma_factsheet.pdf Last accessed 2012 Oct 20.

32. World Health Organization fact sheet No 307: Asthma. 2011. Available at http://www.who.int/mediacentre/factsheets/fs307/en/ [Retrieved 2013 Jan 17]

33. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC) EurRespir J. 1998;12:315–35. [PubMed]

34. Raymond C. Rowe, Paul J. Sheskey, Sian O. Owen; Handbook of Pharmaceutical Excipients, Fifth edition, Pg no: 132-135, 188-191, 389-393, 430-433, 611-616, 701-703, 767-769.

35. Remington: The Science and Practice of Dosage Form Design; 20th edition, Volume II, Chapter 69 – Respiratory Drugs, Pg no: 1297.

36. Remington: The Science and Practice of Dosage Form Design; 20th edition, Volume II, Pg no: 1615-1641.

37. Taylor and Francis; International journal of toxicology: Toxicity of Excipients – A Food and Drug Administration Perspective; 2003; 22(5), Pg no: 377-380.

38. The Merck Index; Thirteen edition, Pg no: 3472.

39. TsingHua, “The pharmacokinetics of Doxofylline in Chinese”. [http://www.shvoong.com/tags/the-pharmacokinetics-of-doxofylline-in-chinese/]

40. US Patent Application 20060147526 file on pharmaceutical formulations comprising anti-asthamatics, such as B-2 adrenoeceptor agonists and xanthines. [http://www.freshpatents.com/pharmaceutical-formulations-comprising---xdf—2-adrenoceptor-agonists-and-xanthines-dt20060706ptan20060147526.PHP]